Cargando…
Efficacy of Sildenafil in Infants with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension
Background: Pulmonary hypertension (PH) is a common comorbidity in infants with bronchopulmonary dysplasia (BPD). Sildenafil is a widely recognized therapy for PH, but its efficacy in infants with BPD is questionable. We propose to assess the efficacy of sildenafil in BPD-associated PH as evaluated...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453183/ https://www.ncbi.nlm.nih.gov/pubmed/37628395 http://dx.doi.org/10.3390/children10081397 |
_version_ | 1785095869240967168 |
---|---|
author | Dillon, Kacie Lamba, Vineet Philip, Ranjit R. Weems, Mark F. Talati, Ajay J. |
author_facet | Dillon, Kacie Lamba, Vineet Philip, Ranjit R. Weems, Mark F. Talati, Ajay J. |
author_sort | Dillon, Kacie |
collection | PubMed |
description | Background: Pulmonary hypertension (PH) is a common comorbidity in infants with bronchopulmonary dysplasia (BPD). Sildenafil is a widely recognized therapy for PH, but its efficacy in infants with BPD is questionable. We propose to assess the efficacy of sildenafil in BPD-associated PH as evaluated based on transthoracic echocardiography (TTE) changes and clinical measures. Methods: Data were retrospectively and prospectively collected. Inclusion criteria were gestational age (GA) < 32 weeks, birth weight (BW) < 1500 g with severe BPD, diagnosis of PH via TTE on sildenafil treatment. PH was evaluated via TTE, which was performed monthly after 36 weeks post-menstrual age (PMA) as a standard of care, and re-reviewed by a single pediatric cardiologist, who was blind to the initial reading. Results: In total, 19 patients were enrolled in the study, having a median GA of 24 3/7 weeks (IQR 23 5/7–25 5/7) and a median BW of 598 g (IQR 572–735). Sildenafil treatment was started at a median PMA of 40.4 weeks. The median respiratory severity score (RSS) at 28 d was 6.5, RSS and FiO2 showed improvement about 12 weeks after starting sildenafil treatment. Conclusions: Improvement in PH was noted via TTE, and patients had improvement in their RSS and FiO2 after prolonged therapy. However, TTE improvements did not correlate with clinical improvements. |
format | Online Article Text |
id | pubmed-10453183 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104531832023-08-26 Efficacy of Sildenafil in Infants with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension Dillon, Kacie Lamba, Vineet Philip, Ranjit R. Weems, Mark F. Talati, Ajay J. Children (Basel) Brief Report Background: Pulmonary hypertension (PH) is a common comorbidity in infants with bronchopulmonary dysplasia (BPD). Sildenafil is a widely recognized therapy for PH, but its efficacy in infants with BPD is questionable. We propose to assess the efficacy of sildenafil in BPD-associated PH as evaluated based on transthoracic echocardiography (TTE) changes and clinical measures. Methods: Data were retrospectively and prospectively collected. Inclusion criteria were gestational age (GA) < 32 weeks, birth weight (BW) < 1500 g with severe BPD, diagnosis of PH via TTE on sildenafil treatment. PH was evaluated via TTE, which was performed monthly after 36 weeks post-menstrual age (PMA) as a standard of care, and re-reviewed by a single pediatric cardiologist, who was blind to the initial reading. Results: In total, 19 patients were enrolled in the study, having a median GA of 24 3/7 weeks (IQR 23 5/7–25 5/7) and a median BW of 598 g (IQR 572–735). Sildenafil treatment was started at a median PMA of 40.4 weeks. The median respiratory severity score (RSS) at 28 d was 6.5, RSS and FiO2 showed improvement about 12 weeks after starting sildenafil treatment. Conclusions: Improvement in PH was noted via TTE, and patients had improvement in their RSS and FiO2 after prolonged therapy. However, TTE improvements did not correlate with clinical improvements. MDPI 2023-08-16 /pmc/articles/PMC10453183/ /pubmed/37628395 http://dx.doi.org/10.3390/children10081397 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Dillon, Kacie Lamba, Vineet Philip, Ranjit R. Weems, Mark F. Talati, Ajay J. Efficacy of Sildenafil in Infants with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension |
title | Efficacy of Sildenafil in Infants with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension |
title_full | Efficacy of Sildenafil in Infants with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension |
title_fullStr | Efficacy of Sildenafil in Infants with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension |
title_full_unstemmed | Efficacy of Sildenafil in Infants with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension |
title_short | Efficacy of Sildenafil in Infants with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension |
title_sort | efficacy of sildenafil in infants with bronchopulmonary dysplasia-associated pulmonary hypertension |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453183/ https://www.ncbi.nlm.nih.gov/pubmed/37628395 http://dx.doi.org/10.3390/children10081397 |
work_keys_str_mv | AT dillonkacie efficacyofsildenafilininfantswithbronchopulmonarydysplasiaassociatedpulmonaryhypertension AT lambavineet efficacyofsildenafilininfantswithbronchopulmonarydysplasiaassociatedpulmonaryhypertension AT philipranjitr efficacyofsildenafilininfantswithbronchopulmonarydysplasiaassociatedpulmonaryhypertension AT weemsmarkf efficacyofsildenafilininfantswithbronchopulmonarydysplasiaassociatedpulmonaryhypertension AT talatiajayj efficacyofsildenafilininfantswithbronchopulmonarydysplasiaassociatedpulmonaryhypertension |